Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396511 · ClinicalTrials.gov registry record · Phase 2
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
A Phase 2 study of Choriocarcinoma, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT02396511: Completed Phase 2 study of Choriocarcinoma, sponsored by Tracon Pharmaceuticals.
NCT02396511 is a Phase 2 study of Choriocarcinoma that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 2 participants, below the 368-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02396511, a Phase 2 study of Choriocarcinoma, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.
Primary Outcome
Progression Free Survival of Two Patients With Metastatic and Refractory Choriocarcinoma determined according to RECIST 1.1 including measurement of serum β- hCG. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions. A 5 mm absolute increase is also required to guard against over calling PD when the tot
Conditions Studied
Interventions
- BIOLOGICAL Bevacizumab
- BIOLOGICAL TRC105
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Insititue - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT02396511 record still lists
NCT02396511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 368-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Choriocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02396511 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02396511 about?
NCT02396511 is a clinical study titled "TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma". The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.
What is the current status of trial NCT02396511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-01. Estimated completion is 2017-12.
What conditions does trial NCT02396511 study?
This clinical trial studies the following conditions: Choriocarcinoma.
What interventions are being tested in trial NCT02396511?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), TRC105 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02396511?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02396511 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choriocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
RECRUITING · Phase 2
-
A Trial for Patients With Gestational Trophoblastic Disease
COMPLETED · Phase 2
-
Molecular Epidemiology of Pediatric Germ Cell Tumors
RECRUITING
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia